Weinbaum S, Tarbell JM, Damiano ER (2007) The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng 9:121–167
Jedlicka J, Becker BF, Chappell D (2020) Endothelial glycocalyx. Crit Care Clin 36:217
Torres LN, Sondeen JL, Ji L, Dubick MA, Torres I (2013) Evaluation of resuscitation fluids on endothelial glycocalyx, venular blood flow, and coagulation function after hemorrhagic shock in rats. J Trauma Acute Care Surg 75:759–766
Schenk S, Schoenhals GJ, de Souza G, Mann M (2008) A high confidence, manually validated human blood plasma protein reference set. BMC Med Genomics 1:41
Pandey S, Vyas GN (2012) Adverse effects of plasma transfusion. Transfusion 52(Suppl 1):65S-79S
Pyne S, Adams DR, Pyne NJ (2016) Sphingosine 1-phosphate and sphingosine kinases in health and disease: recent advances. Prog Lipid Res 62:93–106
Ishii I, Fukushima N, Ye XQ, Chun J (2004) Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 73:321–354
Zeng Y, Adamson RH, Curry FRE, Tarbell JM (2014) Sphingosine-1-phosphate protects endothelial glycocalyx by inhibiting syndecan-1 shedding. Am J Physiol-Heart Circul Physiol 306:H363–H372
Doggett TM, Alves NG, Yuan SY, Breslin JW (2017) Sphingosine-1-phosphate treatment can ameliorate microvascular leakage caused by combined alcohol intoxication and hemorrhagic shock. Sci Rep 7
Adamson RH, Clark JF, Radeva M, Kheirolomoom A, Ferrara KW, Curry FE (2014) Albumin modulates S1P delivery from red blood cells in perfused microvessels: mechanism of the protein effect. Am J Physiol-Heart Circul Physiol 306:H1011–H1017
Diebel ME, Diebel LN, Liberati DM (2019) Protective effects of plasma products on the endothelial-glycocalyx barrier following trauma-hemorrhagic shock: Is sphingosine-1 phosphate responsible? J Trauma Acute Care Surg 87:1061–1069
Zhang GQ, Yang L, Kim GS, Ryan K, Lu SL, O’Donnell RK, Spokes K, Shapiro N, Aird WC, Kluk MJ, Yano K, Sanchez T (2013) Critical role of sphingosine-1-phosphate receptor 2 (S1PR2) in acute vascular inflammation. Blood 122:443–455
Chew WS, Wang W, Herr DR (2016) To fingolimod and beyond: the rich pipeline of drug candidates that target S1P signaling. Pharmacol Res 113:521–532
Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453–21457
Tanasescu R, Constantinescu CS (2014) Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis. Expert Opin Drug Metab Toxicol 10:621–630
Brinkmann V, Cyster JG, Hla T (2004) FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 4:1019–1025
Bonitz JA, Son JY, Chandler B, Tomaio JN, Qin Y, Prescott LM, Feketeova E, Deitch EA (2014) A sphingosine-1 phosphate agonist (FTY720) limits trauma/hemorrhagic shock-induced multiple organ dysfunction syndrome. Shock 42:448–455
Lundblad C, Axelberg H, Grande PO (2013) Treatment with the sphingosine-1-phosphate analogue FTY 720 reduces loss of plasma volume during experimental sepsis in the rat. Acta Anaesthesiol Scand 57:713–718
Hemdan NYA, Weigel C, Reimann CM, Graler MH (2016) Modulating sphingosine 1-phosphate signaling with DOP or FTY720 alleviates vascular and immune defects in mouse sepsis. Eur J Immunol 46:2767–2777
Santos-Gallego CG, Vahl TP, Goliasch G, Picatoste B, Arias T, Ishikawa K, Njerve IU, Sanz J, Narula J, Sengupta PP, Hajjar RJ, Fuster V, Badimon JJ (2016) Sphingosine-1-phosphate receptor agonist fingolimod increases myocardial salvage and decreases adverse postinfarction left ventricular remodeling in a porcine model of ischemia/reperfusion. Circulation 133:954–966
Bürgin-Maunder C, Brooks P, Russell F (2013) Omega-3 fatty acids modulate weibel-palade body degranulation and actin cytoskeleton rearrangement in PMA-Stimulated Human Umbilical Vein Endothelial Cells. Marine Drugs 11(11):4435–4450. https://doi.org/10.3390/md11114435
Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, Claffey K, Hla T (2003) Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 278:47281–47290
Liu JX, Yan ZP, Zhang YY, Wu J, Liu XH, Zeng Y (2016) Hemodynamic shear stress regulates the transcriptional expression of heparan sulfate proteoglycans in human umbilical vein endothelial cell. Cell Mol Biol (Noisy-le-grand) 62:28–34
Yang P, Wei X, Zhang J, Yi B, Zhang GX, Yin L, Yang XF, Sun J (2016) Antithrombotic effects of Nur77 and Nor1 are mediated through upregulating thrombomodulin expression in endothelial cells. Arterioscler Thromb Vasc Biol 36:361–369
Lukas S, Patnaude L, Haxhinasto S, Slavin A, Hill-Drzewi M, Horan J, Modis LK (2014) No differences observed among multiple clinical S1P1 receptor agonists (functional antagonists) in S1P1 receptor down-regulation and degradation. J Biomol Screen 19:407–416
Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, Seuwen K (2009) Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 5:428–434
Wang L, Sammani S, Moreno-Vinasco L, Letsiou E, Wang T, Camp SM, Bittman R, Garcia JG, Dudek SM (2014) FTY720 (s)-phosphonate preserves sphingosine 1-phosphate receptor 1 expression and exhibits superior barrier protection to FTY720 in acute lung injury. Crit Care Med 42:e189-199
Muller HC, Hocke AC, Hellwig K, Gutbier B, Peters H, Schonrock SM, Tschernig T, Schmiedl A, Hippenstiel S, N’Guessan PD, Rosseau S, Suttorp N, Witzenrath M (2011) The sphingosine-1 phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice. Pulm Pharmacol Ther 24:377–385
Becker BF, Jacob M, Leipert S, Salmon AH, Chappell D (2015) Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases. Br J Clin Pharmacol 80:389–402
Barry M, Pati S (2022) Targeting repair of the vascular endothelium and glycocalyx after traumatic injury with plasma and platelet resuscitation. Matrix Biol Plus 14:100107
Diebel LN, Martin JV, Liberati DM (2017) Early tranexamic acid administration ameliorates the endotheliopathy of trauma and shock in an in vitro model. J Trauma Acute Care Surg 82:1080–1086
Jackson-weaver O, Friedman J, Hoof M, Drury R, Packer J, Guidry C, Duchesne J, Rodriguez L (2019) Beta adrenergic receptor activation causes endothelial glycocalyx degradation. Hypertension 74:2
Johansson PI, Henriksen HH, Stensballe J, Gybel-Brask M, Cardenas JC, Baer LA, Cotton BA, Holcomb JB, Wade CE, Ostrowski SR (2017) Traumatic endotheliopathy: a prospective observational study of 424 severely injured patients. Ann Surg 265:597–603
Nelson A, Statkevicius S, Schott U, Johansson PI, Bentzer P (2016) Effects of fresh frozen plasma, Ringer’s acetate and albumin on plasma volume and on circulating glycocalyx components following haemorrhagic shock in rats. Intensive Care Med Exp 4:6
Koo A, Dewey CF Jr, Garcia-Cardena G (2013) Hemodynamic shear stress characteristic of atherosclerosis-resistant regions promotes glycocalyx formation in cultured endothelial cells. Am J Physiol Cell Physiol 304:C137-146
Siren EMJ, Luo HD, Bajaj S, MacKenzie J, Daneshi M, Martinez DM, Conway EM, Cheung KC, Kizhakkedathu JN (2021) An improved in vitro model for studying the structural and functional properties of the endothelial glycocalyx in arteries, capillaries and veins. FASEB J 35:e21643
Hara T, Sato A, Yamamoto C, Kaji T (2021) Syndecan-1 downregulates syndecan-4 expression by suppressing the ERK1/2 and p38 MAPK signaling pathways in cultured vascular endothelial cells. Biochem Biophys Rep 26:101001
Vuong TT, Reine TM, Sudworth A, Jenssen TG, Kolset SO (2015) Syndecan-4 is a major syndecan in primary human endothelial cells in vitro, modulated by inflammatory stimuli and involved in wound healing. J Histochem Cytochem 63:280–292
Bai K, Wang W (2012) Spatio-temporal development of the endothelial glycocalyx layer and its mechanical property in vitro. J R Soc Interface 9:2290–2298
Delgadillo LF, Marsh GA, Waugh RE (2020) Endothelial glycocalyx layer properties and its ability to limit leukocyte adhesion. Biophys J 118:1564–1575
Yoneda A, Lendorf ME, Couchman JR, Multhaupt HA (2012) Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. J Histochem Cytochem 60:9–21
Straat M, Muller MC, Meijers JC, Arbous MS, Spoelstra-de Man AM, Beurskens CJ, Vroom MB, Juffermans NP (2015) Effect of transfusion of fresh frozen plasma on parameters of endothelial condition and inflammatory status in non-bleeding critically ill patients: a prospective substudy of a randomized trial. Crit Care 19:163
Wu F, Peng Z, Park PW, Kozar RA (2017) Loss of syndecan-1 abrogates the pulmonary protective phenotype induced by plasma after hemorrhagic shock. Shock 48:340–345
Milford EM, Reade MC (2019) Resuscitation fluid choices to preserve the endothelial glycocalyx. Crit Care 23:11
Chipman AM, Wu F, Kozar RA (2021) Fibrinogen inhibits microRNA-19b, a novel mechanism for repair of haemorrhagic shock-induced endothelial cell dysfunction. Blood Transfus 19:420–427
Lopez E, Peng ZL, Kozar RA, Cao YN, Ko TC, Wade CE, Cardenas JC (2020) Antithrombin III contributes to the protective effects of fresh frozen plasma following hemorrhagic shock by preventing syndecan-1 shedding and endothelial barrier disruption. Shock 53:156–163
Stahl K, Hillebrand UC, Kiyan Y, Seeliger B, Schmidt JJ, Schenk H, Pape T, Schmidt BMW, Welte T, Hoeper MM, Sauer A, Wygrecka M, Bode C, Wedemeyer H, Haller H, David S (2021) Effects of therapeutic plasma exchange on the endothelial glycocalyx in septic shock. Intensive Care Med Exp 9:16
Emam MN, Abd El-Latif RN (2017) Effect of immunomodulator, fingolimod, on ischemia reperfusion testicular injury in rats: targeting the role of sphingolipid rheostat (fingolimod on I/R induced testicular injury). Alex J Med 53:175–182
Man K, Ng KT, Lee TK, Lo CM, Sun CK, Li XL, Zhao Y, Ho JW, Fan ST (2005) FTY720 attenuates hepatic ischemia–reperfusion injury in normal and cirrhotic livers. Am J Transpl 5:40–49
Wang G, Kim RY, Imhof I, Honbo N, Luk FS, Li K, Kumar N, Zhu BQ, Eberle D, Ching D, Karliner JS, Raffai RL (2014) The immunosuppressant FTY720 prolongs survival in a mouse model of diet-induced coronary atherosclerosis and myocardial infarction. J Cardiovasc Pharmacol 63:132–143
Zhao Y, Shi D, Cao K, Wu F, Zhu X, Wen S, You Q, Zhang K, Liu L, Zhou H (2018) Fingolimod targets cerebral endothelial activation to block leukocyte recruitment in the central nervous system. J Leukoc Biol 103:107–118
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Disclaimer:
This article is autogenerated using RSS feeds and has not been created or edited by OA JF.
Click here for Source link (https://www.springeropen.com/)
